Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cardiac angiosarcoma.

Acta cardiologica·2025

Same author

Comments on association of HbA1c with carotid artery plaques in patients with coronary heart disease.

Acta cardiologica·2023

Same author

[A new approach in coronary interventional cardiology: the distal radial approach].

Revue medicale de Liege·2022

Same author

[Inclisiran (Leqvio®), a potent cholesterol-lowering agent by inhibiting PCSK9 using small interfering RNA-based innovative therapy].

Revue medicale de Liege·2022

Same author

[The wearable cardioverter defibrillator].

Revue medicale de Liege·2022

Same author

[Tricuspid regurgitation: transcatheter treatment by TriClip®].

Revue medicale de Liege·2022

Search research articles

Related Experiment Video

Updated: Dec 6, 2025

Isolation of Atrial Myocytes from Adult Mice

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

[Natriuretic peptides in heart failure].

M L Nguyen Trung¹, J Tridetti¹, A Ancion¹

¹Service de Cardiologie, CHU Liège, Belgique.

Revue Medicale De Liege

|October 8, 2020

Summary

Diagnosing heart failure is complex. Natriuretic peptides, like BNP and NT-proBNP, are key biomarkers, but their correct use requires understanding their specific indications and limitations for accurate clinical practice.

Keywords:

Biomarkers Natriuretic peptides Heart failure

More Related Videos

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Related Experiment Videos

Last Updated: Dec 6, 2025

Isolation of Atrial Myocytes from Adult Mice

Isolation of Atrial Myocytes from Adult Mice

Published on: July 25, 2019

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Area of Science:

Cardiology
Biomarker Research

Background:

Heart failure diagnosis presents challenges due to varied presentations and phenotypes.
Sensitive and specific biomarkers are crucial for accurate heart failure identification.
Natriuretic peptides (ANP, BNP, NT-proBNP) are established heart failure biomarkers.

Purpose of the Study:

To summarize European Society of Cardiology recommendations on natriuretic peptide use.
To enhance understanding and application of natriuretic peptides in clinical settings.
To discuss the role of natriuretic peptides in diagnosing heart failure-related pleural effusions.

Main Methods:

Review and synthesis of European Society of Cardiology guidelines.
Analysis of natriuretic peptide indications, specificities, and limitations.
Exploration of natriuretic peptide utility in etiological diagnosis of pleural effusions.

Main Results:

Natriuretic peptides are validated markers for heart failure.
Proper interpretation necessitates knowledge of their clinical context, including limitations.
Guidelines provide a framework for optimal natriuretic peptide utilization.

Conclusions:

Understanding natriuretic peptide indications and limitations is vital for effective clinical use.
These peptides aid in heart failure diagnosis and management.
Further research supports their role in specific diagnostic scenarios like pleural effusions.